BMS-986453

Study of BMS-986453 in Newly Diagnosed Multiple Myeloma

What will happen during the trial?

This is an open-label study. The investigators propose to examine if BMS-986453 in people with newly diagnosed multiple myeloma may help control their disease for a prolonged period of time despite one-time treatment and challenge continuous treatment which is otherwise prescribed.

More Information

Trial Status
Accepting patients
Trial Phase
Phase 1
Enrollment
25 patients (estimated)
Tags
CAR T Cell, B-Cell Maturation Antigen (BCMA), GPRC5D
Trial Type
Treatment
Last Update
SparkCures ID
2209
NCT Identifier
NCT07333261

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.